Chapter 04 / Entering the World of Clinical Trials / Paid beta preview

Chapter 4: The Project Manager's Mindset

How to move from task tracking to disciplined reality-reading and accountable action. ## 4.1 The Mindset Shift: From Managing Tasks to Reading Reality When people first hear the phrase project manager's mindset, they often expect something motivational. Stay positive. Be proactive. Communicate well. Keep the team aligned. None of those statements is wrong. They are simply too thin for clinical trials. Clinical trial project management is not sustained by cheerful language. It is sustained by disciplined attention. The work asks you to notice what is actually happening before the dashboard admits it, to separate facts from assumptions, to ask what must be true for a plan to work, and to help a room full of experts move toward a responsible decision without pretending the uncertainty has disappeared. That is the mindset shift. Not from negative to positive. From managing tasks to reading reality. Lauren Brooks learned this during RESP-640, a respiratory trial in adults with moderate-to-severe chronic airway disease. The study was randomized [ICH E9], double-blind, active-controlled, and global. Participants were assigned through interactive response technology, or IRT, which handled randomization and study-drug assignment. Investigational product was shipped through regional depots to sites under defined temperature conditions. The protocol required dosing within visit windows, maintenance of the blind, safety follow-up, and tight coordination between supply, site readiness, data, monitoring, and governance. RESP-640 had one of those plans that made everyone feel calmer because it was large. There was a country activation tracker. A site training tracker. An IRT readiness tracker. A drug-supply forecast. A depot shipment plan. A pharmacy manual. A temperature-excursion process. A monitoring plan. A risk register [PMBOK]. A governance calendar. A CRO status deck. A vendor status deck. A dashboard so layered that it could make a nervous executive believe the trial was under control. For a few months, the dashboard behaved. Site activation was not perfect, but acceptable. Randomization was slightly behind plan but recoverable. The CRO reported that monitoring visits were being scheduled. The supply vendor reported that regional depots were stocked. The IRT vendor reported that site access and randomization settings were live for activated sites. The study team held extra meetings during startup and sent more minutes than anyone had time to read. Then a shipment to Site 302 arrived late after a weekend delay in a regional courier route. The temperature monitor showed an excursion: the shipment had briefly moved outside the required storage range during transit. For a beginner, a temperature excursion means the investigational product or comparator was exposed to temperatures outside the defined acceptable range. That does not automatically mean the product is unusable, unsafe, or compromised. It does mean the event must be assessed through the appropriate supply, quality, medical, and documentation process before anyone assumes the product can be used. Michael Tan, our director of clinical supply and randomization operations, joined the issue call with his usual directness. "The kits are quarantined at the site pharmacy," he said. "No participant has received them. The vendor says the excursion is minor and stability can likely support use, but the formal assessment is not complete." Lauren captured the action item. "Supply vendor to provide excursion assessment by Friday." That was fine as far as it went. It did not go far enough. Victor Stein asked, "Does Site 302 have any participants scheduled for randomization before Friday?" Michael checked the IRT report. "Two screening participants are expected to randomize on Thursday if eligibility is confirmed." Maggie Chen looked at the CRO lead. "Does the site know the quarantined kits cannot be dispensed?" The CRO lead said, "The site has been notified that the shipment is under review." Grace Kim did not like that wording. "Under review is not the same as do not use." The room changed. Nothing dramatic had happened yet. No participant had been dosed with questionable product. No randomization error had occurred. No unblinding [ICH E9] had been confirmed. No regulatory report had been triggered. The dashboard could still be green if the team wanted it to be green badly enough. But the trial was speaking. The first version of Lauren's action item treated the problem as a supply deliverable. The better version treated it as a project reality: | Early View | Mature PM View | |---|---| | Vendor owes excursion assessment | What happens before the assessment arrives? | | Site was notified | What exactly was the site told, and who confirmed understanding? | | IRT is live | Could IRT assign a kit that should remain quarantined? | | No dosing has occurred | What prevents dosing from occurring tomorrow? | | Delay is minor | What decision depends on the delayed assessment? | | Issue is tracked | What evidence proves the risk is controlled? | That is the difference between task management and reality reading. A task manager records that the vendor owes an answer. A project manager asks what can go wrong while everyone is waiting for the answer. I do not say this to criticize Lauren. She was doing what many capable PMs do under pressure: capturing the visible

...